(AOF) – Lysogene has entered into a € 15 million loan agreement with the European Investment Bank to accelerate the development of its gene therapy platform. This funding will support the clinical development of the Company’s main drug candidates, and in particular the phase 1/2 clinical trial with LYS-GM101 for the treatment of GM1 gangliosidosis and the launch of preclinical studies with LYS-FXS01 in the fragile X syndrome.
Lysogene will receive the EIB loan in three tranches, namely a first tranche of € 3 million that can be drawn unconditionally, and two other tranches of € 5 and 7 million respectively available upon reaching predefined milestones .
LEXICON
Clinical trials (Phases I, II, III)
Phase I: testing of the molecule on a small scale in humans to assess its safety, tolerance, metabolic and pharmacological properties. Phase II: safety and efficacy evaluation on several hundred patients to identify side effects. Phase III: evaluation of the overall benefit / risk ratio in several thousand patients.
AOF – LEARN MORE
Boost for French pharmacy
At the end of a recent CSIS, the French authorities announced an unprecedented amount of credits (7 billion euros): 1.5 billion for university hospital research, 2 billion for investment in health via bpi France , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenses reimbursed by Medicare will be 2.4%, which should generate growth of at least 0.5% in laboratory turnover,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the actual benefit is sufficient.